In order to improve the design of clinical trials and better conceptualize research plans for the development of anti-infective drugs, it is important to take into consideration cutting-edge drug safety approaches that can be implemented during discovery and early phase studies, as well as promising methods and models for clinical research advancement. In the present text, we describe a holistic perspective inspired by chemoinformatics, systems biology, and predictive clinical pharmacology, to discuss the utility of in silico methods, preclinical models, genomics, translational biomarkers and postmarketing surveillance strategies for safety evaluation and risk detection during anti-infective drug development.
Total Pages: 95-136 (42)
Purchase Chapter
Book Details